UroGen Pharma files patent infringement action against Teva Pharmaceuticals

Teva Pharmaceuticals engages Honeywell to help reduce carbon impact

Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025

Alvotech and Teva get US FDA approval of Selarsdi

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva

Teva confirms efficacy and safety of Ajovy for prevention of migraine

Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month

Teva announces approval of a generic version of Forteo in US

This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024

NATCO launches additional strengths for generic version of Revlimid in USA

Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Alvotech settles with AbbVie to secure US rights to Humira biosimilar

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination